Last reviewed · How we verify

Administration of letrozole

IVI Madrid · Phase 3 active Small molecule

Administration of letrozole is a Aromatase inhibitor Small molecule drug developed by IVI Madrid. It is currently in Phase 3 development for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in early-stage breast cancer, First-line treatment of advanced breast cancer. Also known as: Oral administration of letrozole.

Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women.

Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women. Used for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in early-stage breast cancer, First-line treatment of advanced breast cancer.

At a glance

Generic nameAdministration of letrozole
Also known asOral administration of letrozole
SponsorIVI Madrid
Drug classAromatase inhibitor
TargetAromatase (CYP19A1)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Letrozole selectively inhibits the aromatase enzyme (CYP19A1), which catalyzes the final step of estrogen biosynthesis in peripheral tissues. By reducing estrogen availability, it suppresses the growth of hormone receptor-positive breast cancer cells that depend on estrogen signaling. This mechanism is particularly effective in postmenopausal women where peripheral aromatization is the primary source of estrogen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Administration of letrozole

What is Administration of letrozole?

Administration of letrozole is a Aromatase inhibitor drug developed by IVI Madrid, indicated for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in early-stage breast cancer, First-line treatment of advanced breast cancer.

How does Administration of letrozole work?

Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing circulating estrogen levels in postmenopausal women.

What is Administration of letrozole used for?

Administration of letrozole is indicated for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in early-stage breast cancer, First-line treatment of advanced breast cancer.

Who makes Administration of letrozole?

Administration of letrozole is developed by IVI Madrid (see full IVI Madrid pipeline at /company/ivi-madrid).

Is Administration of letrozole also known as anything else?

Administration of letrozole is also known as Oral administration of letrozole.

What drug class is Administration of letrozole in?

Administration of letrozole belongs to the Aromatase inhibitor class. See all Aromatase inhibitor drugs at /class/aromatase-inhibitor.

What development phase is Administration of letrozole in?

Administration of letrozole is in Phase 3.

What are the side effects of Administration of letrozole?

Common side effects of Administration of letrozole include Hot flashes, Arthralgia/joint pain, Fatigue, Headache, Nausea, Osteoporosis/bone loss.

What does Administration of letrozole target?

Administration of letrozole targets Aromatase (CYP19A1) and is a Aromatase inhibitor.

Related